Focus now on NNZ2591, page-19

I don’t believe the capital raise to be exceptional. Pretty standard fare in the life of a small developing pharma company, and absolutely essential to ensure the company is fiscally above water through its development. You’re right though, a $4 raise is preferable, but at any point in time it is a necessity. I’d be concerned if the company was frequently initiating capital raises instead of being fiscally conservative, but my understanding is Jon Pilcher was the CFO of the previous company he worked at? If so then we have a bean counter at the wheel and that should be reassuring to anyone who’s nervous about frivolous expenditure.